Apligraf

Apligraf

Graftskin Wound care A proprietary manufactured human skin equivalent/artificial skin containing living cells used to cover venous ulcers, burn wounds, diabetic and decubitus ulcers. See Artificial skin.
References in periodicals archive ?
today announced that its Apligraf wound-healing technology has become the first transplant product in Switzerland to receive marketing authorization from Swissmedic for the treatment of venous leg ulcers (VLU) and diabetic foot ulcers (DFU).
Organogenesis announced that its Apligraf bilayered living cellular construct has been approved for the treatment of diabetic foot ulcers and other chronic wounds by the Saudi Food and Drug Authority (SFDA).
NEW ORLEANS -- Apligraf has been used successfully to line a new vagina in a patient with Mayer-Rokitansky-Kuster-Hauser syndrome.
If the ulcers to not health within 12 weeks, the patients will receive Organogenesis' lead product Apligraf to complete the healing process.
AMEX:ORG) has reported that US commercial sales of lead product Apligraf reached 4084 units for the fourth quarter of 2000, up from 3232 units for the previous quarter.
Technically a human organ, the skin is called Apligraf and is grown in an American factory by Swiss Pharmaceutical pioneers Novartis.
Clinical studies have shown that Apligraf in combination with a standard therapy is more efficient in healing diabetic foot ulcers or venous leg ulcers than standard therapy alone.
Canton, MA, announced its lead product Apligraf has been included on the Outpatient Prospective Payment System (OPPS) issued by the US Health Care Financing Administration (HCFA).
8, 2015 /PRNewswire/ -- Three new real-world, comparative effectiveness analyses reporting the clinical outcomes of Apligraf for the treatment of hard-to-heal venous leg ulcers (VLUs), and Dermagraft for the treatment of chronic diabetic foot ulcers (DFUs), were recently presented at the Fall Symposium for Advanced Wound Care (SAWC) annual medical meeting in Las Vegas, Nev.
Novartis Pharmaceuticals Corporation, East Hanover, NJ, announced that the US Food and Drug Administration (FDA) has approved Apligraf for use with conventional diabetic foot ulcer care in the treatment of diabetic foot ulcers (DFU) of greater than 3 weeks duration.
Organogenesis reacquired the marketing rights to Apligraf this year and has begun building its own sales and marketing team to continue uninterrupted supply of the treatment to doctors and patients across the US for treatment of diabetic foot ulcers and venous leg ulcers.
will highlight its growing portfolio of advanced wound care products and present the results of real-world, comparative effectiveness analyses, demonstrating the effectiveness of its Apligraf and Dermagraft living cell-based therapies, compared to Epifix, Primatrix and Theraskin, at the Symposium on Advanced Wound Care (SAWC) Fall Meeting, being held September 26-28, 2015 in Las Vegas, Nev.